FELIX BURDA AWARD 2017: CATEGORY “MEDICINE AND SCIENCE”

Image

burdaThe Felix Burda Award goes to innovative, lasting and exemplary commitments in the area of colorectal cancer.
The category “Medicine and Science” is designed for innovative scientific or medical measures and projects that protect people from colon cancer or allow cancer patients to lead lives worth living. With immediate effect, we accept applications for projects from all European countries provided they raise the prospect of beneficial effects for the fight against colon cancer.

The category “Medicine and Science” covers the following areas:
*       Basic medical research (in areas such as human genetics, tumour biology, molecular genetics, microbioms, tumorigenesis, the infectiology of tumours) and screening measures (including all invasive and non-invasive strategies of early colon cancer recognition, quality assurance and quality management of early colon cancer recognition programmes, structures of implementing screening programmes, risk stratification strategies) designed to research the development of colon cancer, to prevent it and to mitigate its effects.
*       New, original and unusual, evidence-based research and implementation strategies in connection with medical techniques (surgical methods, genetic tests, coloscopy, FIT, capsule endoscopy, virtual coloscopy) that are designed to serve the early detection of colon cancer, to prevent colon cancer and to fight the development of metachronous tumours (primary, secondary and tertiary prevention).
*       Medical measures and research projects with long-term effects that have been or will be implemented and that have or will have a significant impact on the colon cancer mortality rate (such as study invitation procedures and epidemiological studies).
Only projects shall be considered that have been implemented or evaluated, completed or partially completed in 2016 or that have otherwise culminated in the course of the year (through publication, e.g.).
******************************************************************************
For more information please see tender application<http://www.felix-burda-stiftung.de/sites/default/files/documents/Felix%20Burda%20Award%202017%20Tender%20Application_medicine%20and%20science_0.pdf> and application form<http://www.felix-burda-stiftung.de/sites/default/files/documents/Medicine%20and%20Science%20application%20Form%20FBA%202017.pdf> or visit:
http://www.felix-burda-stiftung.de/felix-burda-award/ausschreibung

Felix Burda Stiftung/ Felix Burda Foundation
Arabellastraße 27
81925 München
Fon.: +49-89-9250 1745
Fax: +49-89-9250 2713

Pancreatic Cancer Action: Early Diagnosis Challenge Award.

early-diagnosis-challenge-logo-v2ECP is honored to announce that the “Early Diagnosis Challenge Award Grants” are open for application.  Scientists and researchers are invited to submit.

The Pancreatic Cancer Action is wanting to encourage more research into improving early diagnosis of the UKs fifth biggest cancer killer – pancreatic cancer – so that more patients are diagnosed in time for surgery, currently the only potential for a cure.

Please find the flyer..

Breast Cancer Prevention Study launched

The Breast Cancer Prevention Study has been rigorously prepared by Prof. Russo (Fox Chase Cancer Center – Philadelphia) during almost 2 decennia and is now open for inclusion in Belgian Centers by Prof. Herman Depypere (University Hospital Gent), Prof. Eric de Jonge (ZOL, Genk) and Prof. Jaak Janssens (ECP – Hasselt).

Women at increased risk for breast cancer (carriers of BRCA1&2) are invited to participate. Please check the eligibility criteria and details of the study.

For more information, contact Sabine Janssens.

JFIM Mumbai 2016

Dear colleagues,
For its 15th edition, JFIM will be held in Mumbai, India.
Vietnam, Spain, Hong Kong, Brazil, China, Argentina, Singapore and South Korea have
received in recent years with open arms to our delight, in a spirit of sharing and discovery, both in our professional practices that our cultures. Every meeting, every country we grew and nurtured a still more curious to know. Through its ambitious scientific CME programs,
the JFIM trying to promote French university medical cooperation and Francophonie with
our colleagues around the world. Even if the scale appears modest, it is no less real and palpable if we judge by the success of previous editions, first steps collaborations
stronger between our countries and our universities as internal cross courses,
exchange of files, e-conferences, congresses and various trainings. With over 450,000 online views of our 2015 courses online, JFIM rank among most visited Medical Imaging sites in the world.
The JFIM are pleased and honored to co-host this event with our colleagues from ISVIR,
Indian Society of Vascular and Interventional Radiology, under the aegis of FRI, FRENCH
Federation of interventionnal Radiology and ECP (European Cancer Prevention Organisation). By FEPUR approval , JFIM provides validation
of CME credits.By GEMA (OGDPC aproval), the meeting will provides annual 2016 OGDPC validation for french private MD candidates.
Sincerely yours,
Dr. Luc Rotenberg

Prestigious Award for Dr. Louis Thienpont

OC_163
The International Academy of Cytology (IAC) has selected Dr. Thienpont for the George Wied 2016 life-time award.  The award is attributed at the occasion of the International Congress of the IAC that takes place every 3 year in another continent. In 2016 the 19th International Congress of Cytology (ICC) was held in Yokohama, Japan. Dr. Thienpont is also an extremely competent reviewer of the European Journal of Cancer Prevention. On behalf of ECP we congratulate Dr. Thienpont vividly for this great achievement.

Therapeutic interventions for cancer prevention – the way forward

BACR AND ECMC JOINT MEETING

Therapeutic interventions for cancer prevention – the way forward

 July 18th – 19th 2016
University of Bristol
School of Chemistry

OVERVIEW:

This multidisciplinary meeting will address the enormous opportunities and some of the challenges faced by researchers in the field of therapeutic cancer prevention.  It will draw on examples spanning from ‘bench to bedside’ and beyond, to highlight what advances in basic and translational can bring to the prevention trials of the future.

SESSIONS:

  • Dietary interventions for cancer prevention
  • Aspirin – what else do we need to know?
  • Overcoming barriers to prevention and the way ahead
  • Drug repurposing – what next?
  • New approaches and recent advances

SPEAKERS:

Bernardo Bonnani
Milan, Italy
Farhat Khanim
Birmingham, UK
John Burn
Newcastle, UK
Ruth Langley
London, UK
Rob Coleman
Sheffield, UK
Richard Mithen
Norwich, UK
Jack Cuzick
London, UK
Chris Paraskeva
Bristol, UK
Andrea De Censi
Genova, Italy
Carlo Patrono
Rome, Italy
Farhat Din
Edinburgh, UK
Michael Pollack
Montreal, Canada
Malcolm Dunlop
Edinburgh, UK
Peter Rothwell
Oxford, UK
Michelle Harvie
Manchester, UK
Owen Sansom
Glasgow, UK
Mark Hull
Leeds, UK

ORGANISERS:                                                   DEADLINES:

Karen Brown, Leicester                                        Abstract submission
Ann C Williams, Bristol                                         1st June
Kate Davies, Bristol                                              Early Bird Registration
UKTCPN steering committee                               8th June

 

Info & Registration

STOP project meeting in Porto

2015 STOP PROJECT 2

STOMACH CANCER POOLING (STOP) PROJECT: THIRD PROJECT MEETING – 9th JUNE 2015 – INSTITUTE OF PUBLIC HEALTH – UNIVERSITY OF PORTO – PORTUGAL

The 3rd annual meeting of the Stomach cancer Pooling (StoP) Project was held in Porto, Portugal, on June 9, 2015. The meeting was hosted by Dr. Nuno Lunet and his research team at the Institute of Public Health of the University of Porto (ISPUP).

Main aims of the event were to advance the collaboration between groups participating to the consortium, update them on the progresses of the project, discuss preliminary results and propose new research topics and future developments. The following topics were discussed during the meeting:

 

  1. Major updates from the coordinating centre (release of the harmonized database, subprojects status, project website and new participating studies)
  2. Presentation of new studies joining the consortium, from Japan, Brazil, Spain and Latvia
  3. Presentation of the project “Genetic and lifestyle factors in gastric cancer epidemiology” within the consortium, and update/discussion on availability of biological data
  4. Statistical methods of the project
  5. Presentation and discussion of the results of the first analysis of the project on tobacco smoking and alcohol drinking in relation to the risk of gastric cancer
  6. Proposals for new subproject analyses
  7. Future developments of the StoP Project

 

The meeting was supported by the European Cancer Prevention Organization and by the National Coordination for Oncological Diseases (Portugal).